Small cell lung cancer (SCLC) is an aggressive form of lung cancer with limited therapeutic options, a very high mortality rate and is characterized, in most cases, by neuroendocrine features. A small but important subset of SCLC has intact RB1. However, other characteristics of this subset are not well-defined. To comprehensively assess the underlying genomics of SCLC cell lines with functional RB1, we examined 48 SCLC cell lines from the Cancer Cell Line Encyclopedia (CCLE) collection. Out of these 48 SCLC cell lines, 8 were found to be RB1 WT. We found that RB1 WT SCLC lines are enriched for loss of neuroendocrine lineage markers with CDKN2A inactivation, or CCND1 amplification. Six RB1 WT SCLC cell lines were included in NCI SCLC drug sensitivity screen and two of them were sensitive to CDK4/6 inhibition.
Introduction
Small cell lung cancer (SCLC) is an aggressive form of lung cancer with limited therapeutic options, a very high mortality rate and is characterized, in most cases, by neuroendocrine features. The majority of SCLC are genetically characterized by homozygous inactivation of RB1 and TP53 tumor suppressor genes (1, 2, 3, 4, 5, 6) .
The prevailing hypothesis is that inactivation of RB1 in SCLC leads to increase in cellular proliferation due to loss of cell cycle control and inactivation of TP53 prevents oncogene induced senescence. SCLC diagnosis is commonly based on morphological features of biopsy or cytology samples. A panel of neuroendocrine markers (CHGA, NCAM1, SYP) may also be utilized (7, 8) . In a noticeable fraction of cases, SCLC is present along with another lung cancer subtype(s) such as: large cell neuroendocrine carcinoma, large cell carcinoma, adenocarcinoma, squamous cell carcinoma (9) . A small but important subset of SCLC has intact RB1 (10). However, genomic characteristics and potential therapeutic vulnerabilities of this subset are not welldefined.
Materials and Methods
To comprehensively assess the underlying genomics of SCLC cell lines with functional RB1, we examined 52 SCLC cell lines from the Cancer Cell Line Encyclopedia (CCLE) collection (Supplemental Table S1 ) (11) . These SCLC lines have comprehensive, high quality publicly available genetic and genomic data such as partial exome sequencing, whole exome sequencing, RNA-seq, AFFY SNP 6.0 arrays, and AFFY U133Plus2 mRNA arrays. NCI-H1339 cell line has been recently identified as potentially problematic due to stock contamination with other cell line(s) in some cell lines repositories (12) , NCI-H1694 cell line has RB1 variant of uncertain significance, SHP-77 and DMS454 have low level of RB1 mRNA expression, to avoid potential confounding problems these 4 cell lines were excluded from this analysis.
Results

RB1 status
RB1 can be inactivated by multiple mechanisms, such as loss of function point mutations, deletions, insertions, exon inversions, splice site mutations, and loss of mRNA expression (due to promoter methylation or other mechanisms) (13, 14) . All mechanisms of RB1 inactivation were taken in the account to determine the RB1 status.
In addition to computational checks, RNA-seq data were manually reviewed to be certain, that there were no alterations of RB1 mRNA transcript. The importance of careful review of RB1 status is illustrated by the cell line COR-L24 which has a RB1 splice site mutation NM_000321.2:c.1389+5G>C. This splice site mutation is more than 3 bases away from an exon intron boundary, and therefore is not considered a canonical splice site mutation and may be missed by variant callers. This mutation leads to skipping of exon 14 as illustrated in Supplemental Figure S1 . Out of 48 SCLC cell lines, 8 were found to be RB1 WT and are listed in 
Neuroendocrine status
Regulators of neuroendocrine differentiation such as ASCL1, INSM1, and NEUROD1 are highly expressed in SCLC (20, 21, 22) . However It has been documented over the years that a small fraction of SCLC tumors do not express neuroendocrine lineage markers and transcription factors and is known as SCLC variant (23, 20, 24, 10 Table 1 ; however, SYP is included in Supplemental Table S1 ). In contrast, out of 40 SCLC cell lines with inactivating RB1 alterations or loss of expression (Supplemental Table S1 and at least 2 of them had high CCND1 mRNA expression due to genetic alterations and both also had loss of CDKN2A mRNA expression (1). In the same study, out of 81 tumors with RNA-seq data, 3 had loss of neuroendocrine lineage markers (Supplemental Table S2 ), 2 of these tumors also had high CCND1 mRNA expression and 1 or 2 of these tumors may have had remaining functional RB1.
Therapeutic implications
RB1 WT SCLC cell lines had noticeably lower levels of DLL3 mRNA expression than RB1 altered SCLC cell lines (Supplemental Table S1 ). A DLL3-targeted antibody-drug conjugate rovalpituzumab tesirine is being evaluated in a number of SCLC clinical trials. 
